Medical News

RSS

Cannabis Science to feature in two broadcast radio shows

Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report that it will be featured on two broadcast radio shows beginning tomorrow with Stu Taylor and the “Equity Strategies Show”. Mr. Taylor will interview Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., discussing the Company’s strategies with its FDA Drug approval programs, the Company’s progress to date with its critical drug release programs, and future planning for subsequent drug releases through additional Federal and State government agencies.

23 Sep 2009

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.

23 Sep 2009

New drug test promises to yield quick and effective response for cancer therapy

A group of scientists from Hamburg may have taken a big step towards more effective cancer drug development, Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], heard today (Wednesday 23 September). Dr Ilona Schonn, Director of Cell Culture Research at Indivumed GmbH, told the conference that they had developed a preclinical drug test platform that would enable researchers to analyse tumour tissue for individual patient drug responses on the molecular level.

23 Sep 2009

Sorafenib with chemotherapy for breast cancer patients had a 74% percent improvement in the time they lived

One of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.

23 Sep 2009

Dr. John Clarke polls more than 50,000 votes to win the 2009 H1N1 PSA contest

Department of Health and Human Services (HHS) Secretary Sebelius and Department of Education (ED) Secretary Arne Duncan today announced that Dr. John Clarke of Baldwin, N.Y., is the winner of the 2009 H1N1 PSA Contest. More than 50,000 votes were cast by Americans across the country on YouTube. Dr. Clarke will receive a $2,500 cash prize and his ad will be broadcast on national television.

23 Sep 2009

Improved respiratory health in Mexican women who use vented stoves

Women in Central Mexico who used a vented stove instead of the traditional indoor open fire, experienced improved respiratory health on par with a pack-a-day smoker kicking the habit, according to a recent study.

23 Sep 2009

Organic revitalizing beverage from Sambazon

Sambazon, the global leader in Acai, announces the launch of a powerfully nutritious premium juice line. Antioxidant Elixir(TM) is a organic revitalizing beverage that provides powerful antioxidants and 600% DV Vitamin C, yet remains refreshingly light on calories, sugar, and contains no fat.

23 Sep 2009

Breach notification regulations take effect, HIPAA-covered entities to notify affected individuals if PHI is breached

Today breach notification regulations take effect under the HITECH Act. HIPAA-covered entities, including healthcare providers and business associates, are now required to notify affected individuals, the Secretary of Health and Human Services and sometimes the media, if a patient's unsecured protected health information (PHI) is breached.

23 Sep 2009

Second annual study of FDA drug review released

PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released its second annual study on the state of the U.S. Food and Drug Administration (FDA) drug review process.

From Parexel 23 Sep 2009

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).

23 Sep 2009

GE Healthcare creates a digital wall to commemorate the tenth anniversary of digital mammography

In addition to being Breast Cancer Awareness Month, this October is the tenth anniversary of digital mammography, a technology introduced by GE Healthcare (NYSE:GE) in 1999. Similar to digital photography, digital mammography replaces the film used in traditional mammography with digital files viewed and stored on computers.

23 Sep 2009

KARL STORZ receives LEED Silver certification

KARL STORZ Endoscopy-America, Inc., a leader in diagnostic and operative minimally invasive endoscopic technology, is proud to announce that it has been awarded LEED® (Leadership in Energy and Environmental Design) Silver certification from the U.S. Green Building Council (USGBC) for the company’s North American Headquarters.

23 Sep 2009

PSI to double its HIV prevention programs

PSI (Population Services International) announced two significant commitments today at the Clinton Global Initiative (CGI): a doubling of its HIV prevention programs that target at-risk men and, in partnership with Procter & Gamble's Children's Safe Drinking Water program, a commitment that will expand the availability of safe drinking water to vulnerable populations across the globe.

23 Sep 2009

Bioelectronics files for pre-marketing clearance for its ActiPatch® Therapy products

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced that it filed today with the U.S. Government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy products.

23 Sep 2009

Next Generation CV-3D workstation and software package for Infinix-i X-ray systems

To improve the ability of physicians to provide superior patient care during interventional procedures, Toshiba America Medical Systems, Inc. has introduced its Next Generation CV-3DTM workstation and software package available on the InfinixTM-i X-ray product line.

23 Sep 2009

Livingston Securities announces the agenda for the 2nd Annual Livingston Healthcare Summit.

Today, Scott Livingston, CEO and Founder of Livingston Securities (www.livingstonsecurities.com) announced the agenda for the 2nd Annual Livingston Healthcare and Life Science Stakeholders Summit.

23 Sep 2009

New York State enacts a law to make affordable healthcare available to freelancers

Based on a health insurance model pioneered by Freelancers Union, New York State has enacted a law that will create a demonstration program to provide independent workers – a third of the country’s workforce – with the same quality of health care traditionally offered by employer insurance plans.

23 Sep 2009

DMAA Awards for Beaumont Hospitals and Independence Blue Cross

Health Dialog, a leading provider of healthcare decision programs, today announced that two of its customers received DMAA Awards for excellence in improving overall population-based healthcare.

23 Sep 2009

Aetna selected as sole provider of Medicare Advantage PPO plans to retired state employees

Aetna (NYSE:AET) announced today that it has been selected by the Pennsylvania Employees Benefit Trust Fund (PEBTF) as the sole provider of Medicare Advantage PPO plans to retired state employees. Aetna will be one of three health plans providing Medicare Advantage HMO plans. The contract takes effect Jan. 1, 2010.

23 Sep 2009

Researchers make significant advances in the treatment of metastatic malignant melanoma

Researchers have made significant advances in the treatment of metastatic malignant melanoma - one of the most difficult cancers to treat successfully once it has started to spread - according to a study to be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin on Thursday.

23 Sep 2009

Medical News

Cannabis Science to feature in two broadcast radio shows

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

New drug test promises to yield quick and effective response for cancer therapy

Sorafenib with chemotherapy for breast cancer patients had a 74% percent improvement in the time they lived

Dr. John Clarke polls more than 50,000 votes to win the 2009 H1N1 PSA contest

Improved respiratory health in Mexican women who use vented stoves

Organic revitalizing beverage from Sambazon

Breach notification regulations take effect, HIPAA-covered entities to notify affected individuals if PHI is breached

Second annual study of FDA drug review released

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

GE Healthcare creates a digital wall to commemorate the tenth anniversary of digital mammography

KARL STORZ receives LEED Silver certification

PSI to double its HIV prevention programs

Bioelectronics files for pre-marketing clearance for its ActiPatch® Therapy products

Next Generation CV-3D workstation and software package for Infinix-i X-ray systems

Livingston Securities announces the agenda for the 2nd Annual Livingston Healthcare Summit.

New York State enacts a law to make affordable healthcare available to freelancers

DMAA Awards for Beaumont Hospitals and Independence Blue Cross

Aetna selected as sole provider of Medicare Advantage PPO plans to retired state employees

Researchers make significant advances in the treatment of metastatic malignant melanoma

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News